2019
Clinical validation of reduction in cocaine frequency level as an endpoint in clinical trials for cocaine use disorder
Roos CR, Nich C, Mun CJ, Babuscio TA, Mendonca J, Miguel AQC, DeVito EE, Yip SW, Witkiewitz K, Carroll KM, Kiluk BD. Clinical validation of reduction in cocaine frequency level as an endpoint in clinical trials for cocaine use disorder. Drug And Alcohol Dependence 2019, 205: 107648. PMID: 31677490, PMCID: PMC6910212, DOI: 10.1016/j.drugalcdep.2019.107648.Peer-Reviewed Original ResearchAnhedonia as a Key Clinical Feature in the Maintenance and Treatment of Opioid Use Disorder
Kiluk BD, Yip SW, DeVito EE, Carroll KM, Sofuoglu M. Anhedonia as a Key Clinical Feature in the Maintenance and Treatment of Opioid Use Disorder. Clinical Psychological Science 2019, 7: 1190-1206. PMID: 32042509, PMCID: PMC7009780, DOI: 10.1177/2167702619855659.Peer-Reviewed Original ResearchOpioid use disorderClinical featuresUse disordersHigher anhedonia scoresKey clinical featuresRate of participantsAnhedonia scoresOpioid-dependent sampleOpioid cravingOpioid useTreatment adherenceHealthy controlsSignificant anhedoniaPharmacological interventionsAssessment of anhedoniaMajority of studiesPotential targetAnhedoniaTreatmentTime courseDisordersSignificant knowledge gapsScoresPotential implicationsCritical needDouble‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use
Carroll KM, DeVito EE, Yip SW, Nich C, Sofuoglu M. Double‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use. American Journal On Addictions 2019, 28: 238-245. PMID: 31165574, PMCID: PMC9078084, DOI: 10.1111/ajad.12904.Peer-Reviewed Original ResearchConceptsMethadone-maintained individualsOpioid useSecondary analysisMultiple drugsConcurrent cocaine dependenceTrial of galantaminePlacebo-controlled trialDouble-blind placeboIllicit opioid useRandomized clinical trialsCocaine use disorderGalantamine's effectFuture trialsClinical trialsUrine specimenUrine specimensUse disordersOpioidsCholinesterase inhibitorsMaintenance settingCocaine useCocaine dependencePlaceboConcurrent useGalantamine
2018
Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder
Carroll KM, Nich C, Frankforter TL, Yip SW, Kiluk BD, DeVito EE, Sofuoglu M. Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder. Drug And Alcohol Dependence 2018, 192: 264-270. PMID: 30300800, PMCID: PMC6203294, DOI: 10.1016/j.drugalcdep.2018.08.019.Peer-Reviewed Original ResearchConceptsOpioid use disorderOral naltrexoneUse disordersAffective symptomsVoucher-based contingency managementDysphoric symptomsAffective distressOral naltrexone treatmentMultiple baseline characteristicsBaseline characteristicsNaltrexone treatmentHigh riskNaltrexoneSomatic symptomsSymptomsContingency managementTreatmentHigh rateDistressSubstantial evidenceTrialsTheoretical benefitsDisordersAffective discomfortParticipantsCan neuroimaging help combat the opioid epidemic? A systematic review of clinical and pharmacological challenge fMRI studies with recommendations for future research
Moningka H, Lichenstein S, Worhunsky PD, DeVito EE, Scheinost D, Yip SW. Can neuroimaging help combat the opioid epidemic? A systematic review of clinical and pharmacological challenge fMRI studies with recommendations for future research. Neuropsychopharmacology 2018, 44: 259-273. PMID: 30283002, PMCID: PMC6300537, DOI: 10.1038/s41386-018-0232-4.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsOpioid use disorderOpioid epidemicTreatment responseTask-based fMRI paradigmsUrgent public health problemMedication-assisted treatmentPrescription opioid usersCurrent opioid epidemicPublic health problemEvidence-based treatmentsPaucity of literatureHeroin cuesOpioid medicationsRelapse rateOpioid systemOpioid usersFuture neuroimaging studiesSignificant individual variabilityHealthcare costsWithdrawal effectsHealthy individualsHealth problemsSystematic reviewExtended abstinenceNeuroimaging studiesThe Cholinergic System as a Treatment Target for Opioid Use Disorder
Jensen KP, DeVito EE, Yip S, Carroll KM, Sofuoglu M. The Cholinergic System as a Treatment Target for Opioid Use Disorder. CNS Drugs 2018, 32: 981-996. PMID: 30259415, PMCID: PMC6314885, DOI: 10.1007/s40263-018-0572-y.Peer-Reviewed Original ResearchConceptsCholinergic systemUse disordersTreatment targetsOpioid use disorder epidemicCentral nervous system functionTreatment of OUDEffects of acetylcholineOpioid use disorderTobacco use disorderNervous system functionOpioid medicationsDegrade acetylcholineCurrent treatmentOpioid overdosesPreclinical studiesMedicationsAcetylcholineCholinesterase inhibitorsAlzheimer's diseaseNew treatmentsAccidental deathGlobal healthTreatmentOUDDisease
2016
Anticipatory reward processing among cocaine-dependent individuals with and without concurrent methadone-maintenance treatment: Relationship to treatment response
Yip SW, DeVito EE, Kober H, Worhunsky PD, Carroll KM, Potenza MN. Anticipatory reward processing among cocaine-dependent individuals with and without concurrent methadone-maintenance treatment: Relationship to treatment response. Drug And Alcohol Dependence 2016, 166: 134-142. PMID: 27430401, PMCID: PMC5082418, DOI: 10.1016/j.drugalcdep.2016.07.006.Peer-Reviewed Original ResearchConceptsMethadone maintenance treatmentCocaine-dependent individualsBOLD responseCocaine dependenceSignificant public health problemMethadone-maintained individualsMethadone-maintained populationsMethadone-maintained patientsElevated relapse ratesPublic health problemCocaine-negative urinesCocaine-dependent patientsAnticipatory reward processingPosterior cingulate cortexLoss processingDuration of abstinenceDorsolateral prefrontal cortexCD patientsRelapse rateWhole-brain ANOVAInferior frontal gyrusTreatment outcomesRight caudateHealthy comparison participantsPatients
2014
Pretreatment measures of brain structure and reward-processing brain function in cannabis dependence: An exploratory study of relationships with abstinence during behavioral treatment 1
Yip SW, DeVito EE, Kober H, Worhunsky PD, Carroll KM, Potenza MN. Pretreatment measures of brain structure and reward-processing brain function in cannabis dependence: An exploratory study of relationships with abstinence during behavioral treatment 1. Drug And Alcohol Dependence 2014, 140: 33-41. PMID: 24793365, PMCID: PMC4057888, DOI: 10.1016/j.drugalcdep.2014.03.031.Peer-Reviewed Original ResearchConceptsCannabis-dependent participantsMagnetic resonance imagingCannabis dependenceHC participantsTreatment responseConsecutive abstinenceHealthy comparison menBilateral putamen volumesCannabis-dependent individualsSuccessful treatment outcomeEfficacy of therapeuticsDays of abstinenceVentral striatal activationClinical trialsStriatal functionTreatment outcomesMRI scanningComparison menPutamen volumeResonance imagingBehavioral treatmentBiological markersBrain functionBrain structuresAbstinence
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply